Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study-Reference-Cited by-同舟云学术

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Published:2012-10 Issue:10 Volume:13 Page:983-992
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fizazi Karim,Scher Howard I,Molina Arturo,Logothetis Christopher J,Chi Kim N,Jones Robert J,Staffurth John N,North Scott,Vogelzang Nicholas J,Saad Fred,Mainwaring Paul,Harland Stephen,Goodman Oscar B,Sternberg Cora N,Li Jin Hui,Kheoh Thian,Haqq Christopher M,de Bono Johann S

Publisher

Elsevier BV

Subject

Oncology

Reference37 articles.

1. Secondary hormonal therapy for advanced prostate cancer;Lam;J Urol,2006

2. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer;Crawford;Urology,2009

3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma;Crawford;N Engl J Med,1989

4. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer;Eisenberger;N Engl J Med,1998

5. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis;Scher;J Clin Oncol,2005

Cited by 1190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal;Clinical Genitourinary Cancer;2024-12

2. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer;Clinical and Translational Oncology;2024-09-12

3. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

4. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis;Cells;2024-08-22

5. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16